Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Randomized, Double-Masked, Multicenter Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy of SF0166 Topical Ophthalmic Solution in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)

NCT02914639 is registered in ClinicalTrials.gov with OcuTerra Therapeutics, Inc. as lead sponsor.

NCT NCT02914639
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02914639 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Randomized, Double-Masked, Multicenter Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy of SF0166 Topical Ophthalmic Solution in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)
Lead sponsor
OcuTerra Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
October 5, 2016
Completion date
June 26, 2017
Enrollment
44 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration